Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint [MarketWatch]
CONATUS PHARMACEUTICALS INC (CNAT)
Last conatus pharmaceuticals inc earnings: 11/5 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.conatuspharma.com/investor-relations
Company Research
Source: MarketWatch
Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint Shares of Conatus Pharmaceuticals Inc. CNAT, -57.55% plummeted 53% Thursday after the company announced its Phase 2 clinical trial of emricasan did not meet its primary endpoint. Patients with liver damage from nonalcoholic fatty liver disease did not show sufficient patient improvement on the drug compared to a placebo. Stifel analysts downgraded the company to hold from buy and lowered their price target to $4 from $10, while analysts at SunTrust Robinson Humphrey lowered their price target to $12 from $20. Friday's selloff puts the biotech's stock on track to suffer its biggest one-day percentage decline since the company went public in July 2013. Shares of Conatus have fallen 53% in the year to date, and the S&P 500 SPX, -0.69% has fallen 0.1%. Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.
Show less
Read more
Impact Snapshot
Event Time:
CNAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNAT alerts
High impacting CONATUS PHARMACEUTICALS INC news events
Weekly update
A roundup of the hottest topics